Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actiparin is a pharmaceutical-grade unfractionated heparin sodium derived from bovine intestinal mucosa. It is developed and manufactured by Laboratório Bergamo (an Amneal Pharmaceuticals company) and serves as an anticoagulant. The drug is primarily indicated for patients undergoing cardiovascular surgery requiring cardiopulmonary bypass, where it is used to maintain hemostasis and prevent the formation of thrombi. Actiparin functions by binding to and accelerating the activity of antithrombin III, which in turn inactivates several proteases in the coagulation cascade, most significantly thrombin and Factor Xa. As a bovine-derived product, it offers an alternative to the more common porcine-derived heparins, which is significant for clinical settings in regions where bovine sources are standard or for patients with specific religious or cultural requirements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Actiparin.